Guardant Health, Inc. (NASDAQ:GH) CEO Sells $1,990,332.57 in Stock

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 39,751 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $50.07, for a total transaction of $1,990,332.57. Following the completion of the transaction, the chief executive officer now directly owns 2,147,309 shares of the company's stock, valued at approximately $107,515,761.63. This represents a 1.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The shares were sold at an average price of $50.09, for a total transaction of $3,899,656.77.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The shares were sold at an average price of $50.00, for a total transaction of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84.

Guardant Health Trading Up 3.1%

GH traded up $1.47 during trading on Monday, hitting $49.53. 2,926,769 shares of the company's stock were exchanged, compared to its average volume of 2,130,739. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92. The stock has a 50 day moving average price of $43.05 and a 200 day moving average price of $41.25. The firm has a market cap of $6.14 billion, a P/E ratio of -13.91 and a beta of 1.37.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same period in the previous year, the firm earned ($0.46) earnings per share. Guardant Health's revenue for the quarter was up 20.8% on a year-over-year basis. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on GH. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. TD Securities upped their price target on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. The Goldman Sachs Group upped their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Stephens reaffirmed an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $53.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GH. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 238,037 shares during the period. Entropy Technologies LP purchased a new position in shares of Guardant Health in the fourth quarter valued at $377,000. Van ECK Associates Corp boosted its stake in shares of Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after purchasing an additional 929 shares during the period. Rhumbline Advisers boosted its stake in shares of Guardant Health by 2.2% in the fourth quarter. Rhumbline Advisers now owns 167,230 shares of the company's stock valued at $5,109,000 after purchasing an additional 3,529 shares during the period. Finally, Guyasuta Investment Advisors Inc. purchased a new position in shares of Guardant Health in the fourth quarter valued at $206,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.